Efficacy and Safety of Piracetam Taken for 12 Months in Subjects Suffering From Mild Cognitive Impairment (MCI)

Status:
Completed

Trial end date:
2004-01-01

Target enrollment:

Participant gender:

The purpose of this study was to explore in a more documented way the relative potential and efficacy of piracetam 9600 and 4800 mg daily.

N/A

UCB Pharma

Piracetam